Phase Ib/II study of efficacy and safety of MEK162 plus panitumumab in adult metastatic colorectal cancer patients with mutant or wild-type RAS tumors

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-001986-18

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Phase Ib: To estimate the MTD and/or RP2D of MEK162 in combination with panitumumab Phase II: To assess clinical efficacy of the MEK162 and panitumumab combination


Critère d'inclusion

  • Mutant RAS or wild-type (WT) RAS metastatic colorectal cancer